Prognostic value of CD56 expression in multiple myeloma

Faculty of Medicine

Assiut University

Prognostic value of CD56 expression in multiple myeloma

Research Authors
Salah M Khallaf, Eman A Yousof, Eman H Ahmed, Shymaa G Mansor, Hanan O Mohamed, Sahar Elgammal, Sawsan M Moeen, Doaa M Sayed
Research Date
Research Department
Internal Medicine
Research Journal
Research in Oncology
Research Member
Sawsan Mohamed Moeen Ibrahim
Research Publisher
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Research Vol
Volume 16, Issue 1
Research Website
https://scholar.google.com/scholar?oi=bibs&cluster=288985790268431357&btnI=1&hl=en
Research Year
2020
Research_Pages
6-10
Research Abstract

Background

Understanding the prognostic markers of multiple myeloma (MM) helps in optimizing therapeutic approaches. CD56 is frequently expressed by malignant plasma cells and its use as a prognostic marker in MM is promising.

Aim

To evaluate prognostic value of CD56 expression in patients with MM.

Methods

This study included 50 newly diagnosed patients with MM. Bone marrow samples were analyzed for CD56 expression by flow cytometry. All patients received bortezomib-based therapy for at least 3-4 months.

Results

The median age of patients was 52 years (range 32-75) and 54% of them were males. The stage according to the International Staging System was I in 15 (30%) patients, II in 18 (36%) and III in 17 (34%). CD56 positivity was detected in 84% of enrolled patients. Multivariate analysis revealed that the lack of CD56 expression was an independent predictor of worse overall survival (HR = 4.31 [95% Confidence Interval: 1.23 – 15.13], p = 0.002).

Conclusion

The present study suggests that CD56 negativity is associated with poor prognosis in patients with MM and that its incorporation in the risk panel of MM may be considered. Further studies with larger sample size to validate its prognostic value are needed.